Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice.
Obesity and related metabolic abnormalities are risk factors for colorectal cancer. A state of chronic inflammation and adipocytokine imbalance may play a role in colorectal carcinogenesis. Statins, which are commonly used for the treatment of hyperlipidemia, are known to possess anti-inflammatory effects. Statins also exert chemopreventive properties against various cancers. The present study examined the effects of pitavastatin, a recently developed lipophilic statin, on the development of azoxymethane (AOM)-initiated colonic premalignant lesions in C57BL/KsJ-db/db (db/db) obese mice. Male db/db mice were administrated weekly subcutaneous injections of AOM (15 mg/kg body weight) for 4 weeks and then were subsequently fed a diet containing 1 ppm or 10 ppm pitavastatin for 8 weeks. Feeding with either dose of pitavastatin significantly reduced the number of colonic premalignant lesions, beta-catenin accumulated crypts, by inhibiting proliferation and the surrounding inflammation. Pitavastatin increased the serum levels of adiponectin while conversely decreasing the serum levels of total cholesterol, tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-18, and leptin. Pitavastatin also caused a significant increase in the expression of phosphorylated form of the AMP-activated kinase (AMPK) protein on the colonic mucosa of AOM-treated mice. In addition, the expression levels of TNF-alpha, IL-6, IL-18, and COX-2 mRNAs on the colonic mucosa of AOM-treated mice were decreased by treatment with this agent. These findings suggest that pitavastatin attenuates chronic inflammation and improves the imbalance of adipocytokines, both of which are caused by the presence of excess adipose tissues, thereby preventing the development of colonic premalignancies in an obesity-related colon cancer model. Therefore, some types of statins, including pitavastatin, may be a useful chemoprevention modality for colon cancer in obese individuals.
Yasuda
Yoichi
Y
Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Shimizu
Masahito
M
Shirakami
Yohei
Y
Sakai
Hiroyasu
H
Kubota
Masaya
M
Hata
Kazuya
K
Hirose
Yoshinobu
Y
Tsurumi
Hisashi
H
Tanaka
Takuji
T
Moriwaki
Hisataka
H
D000818:Animals; D001397:Azoxymethane / Q000633:toxicity*; D002273:Carcinogens / Q000633:toxicity; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000150:complications / Q000473:pathology / Q000517:prevention & control*; D016207:Cytokines / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007249:Inflammation / Q000517:prevention & control; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D011230:Precancerous Conditions / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D011804:Quinolines / Q000627:therapeutic use*
D002273:Carcinogens; D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; C108475:pitavastatin; D001397:Azoxymethane
Int J Oncol. 2009 Feb;34(2):339-44
19148467
Gut. 2008 Nov;57(11):1531-8
18676419
JAMA. 2008 Oct 1;300(13):1523-31
18827209
Clin Chim Acta. 2007 May 1;380(1-2):24-30
17343838
Carcinogenesis. 2008 May;29(5):1057-63
18375960
Int J Cancer. 2007 Jan 15;120(2):252-8
17066427
Cancer Res. 2007 Jul 15;67(14):6745-52
17638885
J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94
16288122
Clin Cancer Res. 2009 May 1;15(9):3068-75
19366832
Obes Rev. 2007 Sep;8(5):395-408
17716297
Nat Rev Cancer. 2001 Oct;1(1):11-21
11900248
Gut. 2006 Feb;55(2):285-91
16239255
Carcinogenesis. 2004 May;25(5):821-5
14729596
Int J Cancer. 2008 Aug 15;123(4):951-7
18521906
Carcinogenesis. 2003 Jun;24(6):1015-9
12807742
Science. 1996 Feb 2;271(5249):665-8
8571133
Circulation. 2001 Jan 23;103(3):357-62
11157685
Int J Cancer. 2004 Mar;109(1):149-52
14735482
JAMA. 1997 Jul 23-30;278(4):313-21
9228438
N Engl J Med. 2005 May 26;352(21):2184-92
15917383
Nat Rev Cancer. 2005 Dec;5(12):930-42
16341084
Cancer Prev Res (Phila). 2008 Oct;1(5):369-75
19138981
Cancer Res. 2001 Mar 1;61(5):1874-8
11280741
Eur J Cancer. 2006 Apr;42(6):745-50
16517151
Endocr Rev. 2005 May;26(3):439-51
15897298
Carcinogenesis. 2003 Jan;24(1):107-11
12538355
Lancet. 2005 Oct 8;366(9493):1267-78
16214597
Expert Opin Pharmacother. 2007 Oct;8(14):2315-27
17927486
Toxicol Lett. 2000 Mar 15;112-113:395-402
10720758
Am J Physiol Endocrinol Metab. 2001 May;280(5):E745-51
11287357
Am J Physiol Regul Integr Comp Physiol. 2002 May;282(5):R1429-35
11959686
Cancer Prev Res (Phila). 2009 Apr;2(4):301-9
19336731
Mutat Res. 2004 May;566(3):191-208
15082237
Circulation. 2004 Jun 1;109(21 Suppl 1):II18-26
15173059
Jpn J Cancer Res. 2002 Mar;93(3):242-6
11927004
Atherosclerosis. 2009 Jun;204(2):483-90
18977478
Science. 1993 Jan 1;259(5091):87-91
7678183
Am J Pathol. 1993 Jun;142(6):1858-65
8506954
Cancer Res. 2007 May 1;67(9):4079-87
17483318
J Nutr Biochem. 2006 Mar;17(3):145-56
16426829
Int J Cancer. 2007 Nov 15;121(10):2331-9
17657716
Cancer Prev Res (Phila). 2008 Sep;1(4):298-304
19138973
Chem Biol Interact. 2005 Jun 30;155(1-2):1-9
15904905
Horm Metab Res. 2007 Apr;39(4):250-5
17447161
Mol Med Rep. 2008 May-Jun;1(3):355-61
21479417
Cancer Lett. 2007 Mar 8;247(1):115-21
16797120
J Cell Biochem. 2009 Apr 15;106(6):975-83
19224538
Biomed Pharmacother. 2004 Dec;58(10):614-8
15589072
Diabetologia. 2003 May;46(5):595-607
12764580
Cancer Sci. 2004 Apr;95(4):316-20
15072589
Gastroenterology. 2007 May;132(6):2208-25
17498513
Obes Surg. 2003 Aug;13(4):615-21
12935365